# Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3A

> **NCT03624959** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 100 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** Ozanimod
- **DRUG:** Gemfibrozil
- **DRUG:** Itraconazole
- **DRUG:** Rifampin

## Key facts

- **NCT ID:** NCT03624959
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-20
- **Primary completion:** 2018-08-10
- **Final completion:** 2018-08-10
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2019-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03624959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03624959, "Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3A". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03624959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*